ABBV Revenue
Revenue at AbbVie rose to $61.2B in fiscal 2025, the highest in the 5 years reported, from $56.3B in 2024.
Total revenues as filed (us-gaap fallback chain; for financials, net revenue or net interest income). Source tag recorded per name.
SOURCE: us-gaap:Revenues · EDGAR CompanyFacts · CIK 1551152 · EDGAR ↗ · FY2021–FY2025 · ANNUAL
History AS FILED · DERIVATION SHOWN WHERE DERIVED
| Fiscal year | Revenue | Change |
|---|---|---|
| FY2025 | $61.2B | +$4.8B |
| FY2024 | $56.3B | +$2.0B |
| FY2023 | $54.3B | $-3.7B |
| FY2022 | $58.1B | +$1.9B |
| FY2021 | $56.2B | — |
Cross-checks touching this measure FROM THE FILING REVIEW
✓ MATCHESfull year results
Every quoted figure reconciles to the filed lines: $61.2 billion against total revenues; $15.1 billion against operating income; $2.36 against diluted earnings per share.
FY2025 10-K · FULL RECONCILIATION →✓ MATCHESrevenue growth rate
Every quoted figure reconciles to the filed lines: 9% against total revenues.
FY2025 10-K · FULL RECONCILIATION →◐ PARTLYSG&A leverage
The selling, general and administrative line moved as stated — $14.8B to $14.0B. The drivers management names are not separately disclosed on the face statements; carried as partly supported.
FY2025 10-K · FULL RECONCILIATION →◐ WATCHInventory vs revenue pace
Inventory grew +9.8pp faster than revenue. Carried as watch (7pp threshold).
FY2025 10-K · FULL RECONCILIATION →✓ CLEANReceivables pace
Days sales outstanding moved +4.4 days — inside the ±7-day watch threshold.
FY2025 10-K · FULL RECONCILIATION →More SAME DATA, OTHER VIEWS
Revenue across coverage → · ABBV company view →
Net income · Operating cash flow · Free cash flow · Capital expenditure · Cash & equivalents · Total assets · Shareholders' equity · Total debt · Return on equity · Days sales outstanding
Not investment advice. Every figure on this page is an XBRL fact from the issuer's own SEC filings or an arithmetic over such facts with the method shown. No forecast is made; no posture is expressed.